Summary
Boston Scientific Corporation (BSX) announced the completion of its acquisition of the global surgical business of Lumenis LTD. on September 1, 2021. This strategic move, previously agreed upon in March 2021 for approximately $1.07 billion in cash, significantly expands BSX's offerings in the urology and otolaryngology sectors. The acquired Lumenis surgical business is known for its premier laser systems, fibers, and accessories. This integration is expected to enhance Boston Scientific's existing portfolio and drive growth by offering more comprehensive solutions to healthcare providers and patients in these key surgical specialties. Investors should monitor the integration progress and its impact on future financial performance.
Key Highlights
- 1Boston Scientific (BSX) has successfully completed the acquisition of Lumenis' global surgical business.
- 2The acquisition cost was approximately $1.07 billion in cash, subject to closing adjustments.
- 3The acquired business focuses on laser systems, fibers, and accessories for urology and otolaryngology procedures.
- 4This acquisition strengthens BSX's position in the surgical market, particularly in urology and otolaryngology.
- 5The transaction was completed following the satisfaction of customary closing conditions.
- 6A press release detailing the acquisition is included as an exhibit to the 8-K filing.